Additionally, acute myeloid leukemia with NPM1 mutations (without FLT3–ITD) or in-frame CEBPA mutations in the basic leucine zipper region is now categorized as favorable-risk due to its heightened sensitivity to chemotherapy [1,40]. This evidence concerns the gene FLT3 and acute myeloid leukemia.